TORNTPHARM · NSE Healthcare Large Cap

Torrent Pharmaceuticals Limited

TORNTPHARM  ·  National Stock Exchange of India

TORNTPHARM is currently trading at ₹4,524, 6.5% below its 50-day moving average. The Kasauti methodology audit finds 5 of 8 structural parameters confirmed, placing this instrument in the Does Not Pass Yet category.

Data Execution Timestamp: 23 October 2026 · NSE Closing Bell
Overall Verdict
अभी नहीं मित्र
Does Not Pass Yet
Minervini SEPA 5 / 8
Weinstein Stage Stage 1 — Base
Base Advance Top Decline
52-Week Price History — Weekly
₹4.52k Snapshot · NSE Closing Bell · 23 Oct 2026
₹3.1k ₹3.7k ₹4.3k ₹4.8k ₹5.4k Oct '25 Jan '26 Apr '26 Jul '26 Oct '26 52W H ₹5.1k
Weekly close 50 DMA 200 DMA 52W high

Minervini SEPA — 8 Parameter Audit

Parameter Result Data
Price above 150 & 200 DMA
Minervini SEPA · Criterion 1
FAIL Price ₹4,524 · 150 DMA ₹4,615 · 200 DMA ₹4,486
150 DMA above 200 DMA
Minervini SEPA · Criterion 2
PASS 150 DMA ₹4,615 vs 200 DMA ₹4,486 (+2.9%)
200 DMA trending up ≥ 1 month
Minervini SEPA · Criterion 3
PASS 200 DMA slope: +1.87% over 4 weeks
50 DMA above 150 & 200 DMA
Minervini SEPA · Criterion 4
PASS 50 DMA ₹4,841 · 150 DMA ₹4,615 · 200 DMA ₹4,486
Price above 50 DMA
Minervini SEPA · Criterion 5
FAIL Price ₹4,524 · 50 DMA ₹4,841 (-6.5%)
Price within 25% of 52-week high
Minervini SEPA · Criterion 6
PASS ₹4,524 vs 52W high ₹5,250 (-13.8%)
Price ≥ 30% above 52-week low
Minervini SEPA · Criterion 7
FAIL ₹4,524 vs 52W low ₹3,502 (+29.2%)
RS Rating ≥ 70
Minervini SEPA · Criterion 8
PASS RS Rating: 76 (threshold: ≥70)

Weinstein Stage Analysis

Stage 1
Base
Stage 2
Advance
Stage 3
Top
Stage 4
Decline

TORNTPHARM.NS is in Weinstein Stage 1 — the basing phase. The stock is consolidating after a prior decline, trading sideways around or below its 200-day moving average. Position traders applying strict methodology do not participate during Stage 1.

Relative Strength Rating

76 Stronger than 76% of the NSE universe
↓ Declining over 13 weeks

Structural Analysis

Torrent Pharmaceuticals Limited is currently trading 6.5% below its 50-day moving average, with Weinstein Stage 1 confirmed by the moving average hierarchy.

The Minervini SEPA audit finds 5 of 8 parameters confirmed. The parameter(s) not confirmed: Price above 150 & 200 DMA, Price above 50 DMA, 30% above 52W low.

Sanjaya's Reading

The Witness Speaks

Mitra, main dekh raha hoon Torrent Pharmaceuticals Limited ko — 5 criteria poore hain aath mein se.

Weinstein Stage 1 mein hai yeh instrument. अभी नहीं मित्र.

This is a static snapshot

This audit was generated from NSE closing data on 23 October 2026. Run a live audit with real-time data, animated criteria reveals, and Sanjaya's full narration.

Run a Live Audit — Free →

Free tier includes Nifty 50 stocks · Pro unlocks full NSE universe

Frequently Asked Questions

Does TORNTPHARM pass the Minervini SEPA criteria?▾

TORNTPHARM (Torrent Pharmaceuticals Limited) currently meets 5 of 8 Minervini SEPA parameters. TORNTPHARM currently meets 5 of 8 Minervini SEPA parameters. The parameter(s) not confirmed: Price above 150 & 200 DMA, Price above 50 DMA, 30% above 52W low.

What is the Weinstein Stage Analysis for TORNTPHARM?▾

TORNTPHARM is currently in Weinstein Stage 1. TORNTPHARM.NS is in Weinstein Stage 1 — the basing phase. The stock is consolidating after a prior decline, trading sideways around or below its 200-day moving average. Position traders applying strict methodology do not participate during Stage 1.

Is TORNTPHARM structurally aligned for position trading?▾

The Kasauti verdict for TORNTPHARM is अभी नहीं मित्र (Does Not Pass Yet). The Kasauti verdict for TORNTPHARM.NS is अभी नहीं मित्र — Does Not Pass Yet. With 5 of 8 criteria met, the primary area to monitor is: Price above 150 & 200 DMA, Price above 50 DMA, 30% above 52W low. This is a structural methodology assessment only — not a recommendation to deploy or exit capital. This is a structural methodology assessment only — not a recommendation to deploy or exit capital.

Methodology Assessment Disclaimer: This page presents a systematic structural audit of TORNTPHARM against methodology parameters derived from the published works of Mark Minervini and Stan Weinstein. All data is sourced from NSE end-of-day prices. This content is for educational and analytical purposes only. Kasauti™ does not provide investment advice, stock recommendations, or capital deployment directives. Always conduct independent research and consult a SEBI-registered investment adviser before making any financial decisions.